Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology
Public health threats such as the current COVID-19 pandemics have required prompt action by the local, national, and international authorities. Rapid and noninvasive diagnostic methods may provide on-site detection and immediate social isolation, used as tools to rapidly control virus spreading. Acc...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488804/?tool=EBI |
| _version_ | 1811204451337240576 |
|---|---|
| author | Meila Bastos De Almeida Regina Aharonov-Nadborny Eran Gabbai Ana Paula Palka Leticia Schiavo Elis Esmanhoto Irina Riediger Jaime Rocha Ariel Margulis Marcelo Loureiro Christina Pettan-Brewer Louise Bach Kmetiuk Ivan Roque De Barros-Filho Alexander Welker Biondo |
| author_facet | Meila Bastos De Almeida Regina Aharonov-Nadborny Eran Gabbai Ana Paula Palka Leticia Schiavo Elis Esmanhoto Irina Riediger Jaime Rocha Ariel Margulis Marcelo Loureiro Christina Pettan-Brewer Louise Bach Kmetiuk Ivan Roque De Barros-Filho Alexander Welker Biondo |
| author_sort | Meila Bastos De Almeida |
| collection | DOAJ |
| description | Public health threats such as the current COVID-19 pandemics have required prompt action by the local, national, and international authorities. Rapid and noninvasive diagnostic methods may provide on-site detection and immediate social isolation, used as tools to rapidly control virus spreading. Accordingly, the aim of the present study was to evaluate a commercial breath analysis test (TERA.Bio®) and deterministic algorithm for detecting the SARS-CoV-2 spectral signature of Volatile Organic Compounds present in exhaled air samples of suspicious persons from southern Brazil. A casuistic total of 70 infected and 500 non-infected patients were sampled, tested, and results later compared to RT-qPCR as gold standard. Overall, the test showed 92.6% sensitivity and 96.0% specificity. No statistical correlation was observed between SARS-CoV-2 positivity and infection by other respiratory diseases. Further studies should focus on infection monitoring among asymptomatic persons. In conclusion, the breath analysis test herein may be used as a fast, on-site, and easy-to-apply screening method for diagnosing COVID-19. |
| first_indexed | 2024-04-12T03:13:22Z |
| format | Article |
| id | doaj.art-9efe81badb4a44d490b7f9d8798f44cf |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T03:13:22Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-9efe81badb4a44d490b7f9d8798f44cf2022-12-22T03:50:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01179Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technologyMeila Bastos De AlmeidaRegina Aharonov-NadbornyEran GabbaiAna Paula PalkaLeticia SchiavoElis EsmanhotoIrina RiedigerJaime RochaAriel MargulisMarcelo LoureiroChristina Pettan-BrewerLouise Bach KmetiukIvan Roque De Barros-FilhoAlexander Welker BiondoPublic health threats such as the current COVID-19 pandemics have required prompt action by the local, national, and international authorities. Rapid and noninvasive diagnostic methods may provide on-site detection and immediate social isolation, used as tools to rapidly control virus spreading. Accordingly, the aim of the present study was to evaluate a commercial breath analysis test (TERA.Bio®) and deterministic algorithm for detecting the SARS-CoV-2 spectral signature of Volatile Organic Compounds present in exhaled air samples of suspicious persons from southern Brazil. A casuistic total of 70 infected and 500 non-infected patients were sampled, tested, and results later compared to RT-qPCR as gold standard. Overall, the test showed 92.6% sensitivity and 96.0% specificity. No statistical correlation was observed between SARS-CoV-2 positivity and infection by other respiratory diseases. Further studies should focus on infection monitoring among asymptomatic persons. In conclusion, the breath analysis test herein may be used as a fast, on-site, and easy-to-apply screening method for diagnosing COVID-19.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488804/?tool=EBI |
| spellingShingle | Meila Bastos De Almeida Regina Aharonov-Nadborny Eran Gabbai Ana Paula Palka Leticia Schiavo Elis Esmanhoto Irina Riediger Jaime Rocha Ariel Margulis Marcelo Loureiro Christina Pettan-Brewer Louise Bach Kmetiuk Ivan Roque De Barros-Filho Alexander Welker Biondo Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology PLoS ONE |
| title | Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology |
| title_full | Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology |
| title_fullStr | Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology |
| title_full_unstemmed | Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology |
| title_short | Clinical trial and detection of SARS-CoV-2 by a commercial breath analysis test based on Terahertz technology |
| title_sort | clinical trial and detection of sars cov 2 by a commercial breath analysis test based on terahertz technology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488804/?tool=EBI |
| work_keys_str_mv | AT meilabastosdealmeida clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT reginaaharonovnadborny clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT erangabbai clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT anapaulapalka clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT leticiaschiavo clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT elisesmanhoto clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT irinariediger clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT jaimerocha clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT arielmargulis clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT marceloloureiro clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT christinapettanbrewer clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT louisebachkmetiuk clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT ivanroquedebarrosfilho clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology AT alexanderwelkerbiondo clinicaltrialanddetectionofsarscov2byacommercialbreathanalysistestbasedonterahertztechnology |